JP7627259B2 - 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ） - Google Patents

抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ） Download PDF

Info

Publication number
JP7627259B2
JP7627259B2 JP2022506056A JP2022506056A JP7627259B2 JP 7627259 B2 JP7627259 B2 JP 7627259B2 JP 2022506056 A JP2022506056 A JP 2022506056A JP 2022506056 A JP2022506056 A JP 2022506056A JP 7627259 B2 JP7627259 B2 JP 7627259B2
Authority
JP
Japan
Prior art keywords
tumor
cancer
conjugate
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506056A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021021882A5 (https=
JP2022543765A (ja
JP2022543765A5 (https=
Inventor
ミゲル ガルシア－グスマン
ロジャー ハイム
ジェリー フォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakuten Medical Inc
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of JP2022543765A publication Critical patent/JP2022543765A/ja
Publication of JPWO2021021882A5 publication Critical patent/JPWO2021021882A5/ja
Publication of JP2022543765A5 publication Critical patent/JP2022543765A5/ja
Application granted granted Critical
Publication of JP7627259B2 publication Critical patent/JP7627259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022506056A 2019-07-30 2020-07-29 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ） Active JP7627259B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880514P 2019-07-30 2019-07-30
US62/880,514 2019-07-30
US201962896453P 2019-09-05 2019-09-05
US62/896,453 2019-09-05
US201962931405P 2019-11-06 2019-11-06
US62/931,405 2019-11-06
PCT/US2020/043999 WO2021021882A1 (en) 2019-07-30 2020-07-29 Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antybody-phthalocyanine dye conjugate and anti-pd1 antibody

Publications (4)

Publication Number Publication Date
JP2022543765A JP2022543765A (ja) 2022-10-14
JPWO2021021882A5 JPWO2021021882A5 (https=) 2023-08-04
JP2022543765A5 JP2022543765A5 (https=) 2023-08-04
JP7627259B2 true JP7627259B2 (ja) 2025-02-05

Family

ID=72047165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506056A Active JP7627259B2 (ja) 2019-07-30 2020-07-29 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）

Country Status (6)

Country Link
US (1) US20220313822A1 (https=)
EP (1) EP4004048A1 (https=)
JP (1) JP7627259B2 (https=)
CN (1) CN114423453A (https=)
TW (1) TW202118518A (https=)
WO (1) WO2021021882A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
TW202133886A (zh) * 2019-12-06 2021-09-16 美商樂天醫藥生技股份有限公司 用於增強免疫及腫瘤治療之方法
CA3260932A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD25-SPECIFIC ANTIBODIES AND THEIR USES
EP4662238A1 (en) * 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522055A (ja) 2015-08-07 2018-08-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ がんを処置するためのサプレッサー細胞の近赤外光免疫療法（ｎｉｒ−ｐｉｔ）
JP2018528268A (ja) 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド 光免疫療法のための組成物、組み合わせおよび関連方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781495A (zh) * 2011-07-11 2014-05-07 美国政府(由卫生和人类服务部的部长所代表) 光敏抗体-荧光团缀合物
SG11201610052TA (en) * 2014-08-08 2017-02-27 Us Health Photo-controlled removal of targets in vitro and in vivo
RU2740793C2 (ru) 2016-10-25 2021-01-21 Ракутен Медикал, Инк. Светорассеивающие устройства для использования в фотоиммунотерапии
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
CA3096305A1 (en) * 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522055A (ja) 2015-08-07 2018-08-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ がんを処置するためのサプレッサー細胞の近赤外光免疫療法（ｎｉｒ−ｐｉｔ）
JP2018528268A (ja) 2015-08-18 2018-09-27 アスピリアン セラピューティクス インコーポレイテッド 光免疫療法のための組成物、組み合わせおよび関連方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACC． Chem. Res.，2019年07月23日，Vol.52，pp.2332-2339
癌と化学療法，2019年01月，Vol.46, No.1，pp.28-33

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505556A (ja) * 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法

Also Published As

Publication number Publication date
CN114423453A (zh) 2022-04-29
WO2021021882A1 (en) 2021-02-04
US20220313822A1 (en) 2022-10-06
JP2022543765A (ja) 2022-10-14
TW202118518A (zh) 2021-05-16
EP4004048A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7627259B2 (ja) 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US20190365897A1 (en) Therapeutic compositions and related methods for photoimmunotherapy
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
US9132281B2 (en) Focused radiation for augmenting immune-based therapies against neoplasms
ES2563439T5 (es) Medios y métodos para tratar LDCBG
JP2022003043A (ja) 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JPWO2019189780A1 (ja) 癌の治療及び／又は予防用医薬組成物
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
US20230028062A1 (en) Methods for enhancing immunity and tumor treatment
KR20080091427A (ko) 동시 화학요법 및 면역요법
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
JP2020531437A (ja) ｈａＮＫセツキシマブ併用及び方法
JP2022130602A (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用
JP2019513826A (ja) 放射線療法の改善
HK40092801A (zh) 用於治疗癌症的纳米颗粒组合物
JP2018527010A (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたＴ細胞およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230727

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250124

R150 Certificate of patent or registration of utility model

Ref document number: 7627259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150